Loading
A phase 3 trial of Zilovertamab vedotin, Rituximab, Cyclophosphamide in diffuse large b-cell lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) is a phase 3 interventional study registered as NCT06717347 by Merck Sharp & Dohme LLC, with 1046 participants planned, started 2025-01-27 and due to reach its primary completion in 2029-07-02. Interventions recorded: Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
Shares Zilovertamab vedotin, Prednisone, Rituximab, Doxorubicin.
Shares Zilovertamab vedotin, Prednisone, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.